A new study from a Massachusetts General Hospital (MGH) research team has found that the hypertension drug losartan, which targets the angiotensin signalling pathway, may improve the effectiveness of chemotherapy agents used to treat ovarian cancer.
Previous research from the same team identified a similar effect for losartan in animal models of breast and pancreatic cancer, leading to a phase 2 clinical trial that had promising results against pancreatic cancer.
"We know that solid stress imposed by growing cancer cells and the extracellular matrix molecules they produce can compress blood vessels, reducing delivery of drugs and oxygen to tumorus," says Lei Xu, PhD, of the Steele Laboratories for Tumour Biology in the MGH Department of Radiation Oncology, co-senior author of the report published in PNAS.
"The extracellular matrix itself can keep high-molecular-weight drugs from penetrating tumours, and angiotensin signalling contributes to matrix formation. Since levels of an important enzyme in the angiotensin pathway are elevated and associated with poor outcomes in ovarian cancer, we investigated whether use of losartan to decrease fibrosis could improve outcomes in animal models of ovarian cancer."
In a series of experiments in two mouse models the investigators found the following:
An analysis of records of patients who received standard treatment for ovarian cancer at MGH or Brigham and Women's Hospital while also also being treated for hypertension found that those patients taking losartan or other angiotensin-targeting drugs at the time of diagnosis lived an average of 30 months longer than did those taking other hypertension drugs.
"The entire class of angiotensin-targeting drugs that includes losartan has been shown to reduce collagen accumulation in cardiac and renal fibrotic disease," says Xu, who is an assistant professor of Radiation Oncology at Harvard Medical School (HMS).
"Losartan is a safe, and inexpensive drug that would cost less than $1/day while making a significant difference for patients with ovarian cancer."
Rakesh K. Jain, PhD, director of the Steele Labs, A.W. Cook Professor of Radiation Oncology at HMS and co-senior author of the PNAS report, adds, "Our findings - on top of the the beneficial results of the recent phase 2 trial for pancreatic cancer - should provide information and tools to explore a new therapeutic target for ovarian cancer, which leads to the death of around 14,000 women in the U.S. each year."
Source: Massachusetts General Hospital